Safe and effective treatment of seborrheic dermatitis

Cutis

Volumn 83, Issue 6, 2009, Pages 333-338

  Elewski, Boni E ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFLAMMATORY AGENT; IMIDAZOLE DERIVATIVE; KERATOLYTIC AGENT; SERTACONAZOLE; THIOPHENE DERIVATIVE;

ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HUMAN; INTRADERMAL DRUG ADMINISTRATION; MALASSEZIA; MALE; MICROBIOLOGY; PATIENT COMPLIANCE; RECURRENT DISEASE; RISK FACTOR; SEBORRHEIC DERMATITIS;

ADMINISTRATION, CUTANEOUS; ANTI-INFLAMMATORY AGENTS; ANTIFUNGAL AGENTS; CLINICAL TRIALS AS TOPIC; DERMATITIS, SEBORRHEIC; FEMALE; HUMANS; IMIDAZOLES; KERATOLYTIC AGENTS; MALASSEZIA; MALE; MEDICATION ADHERENCE; RECURRENCE; RISK FACTORS; THIOPHENES;

EID: 68349113810     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Gupta AK, Bluhm R. Seborrheic dermatitis. J Eur Acad Dermatol Venereol. 2004;18:13-26.
2. Johnson BA, Nunley JR. Treatment of seborrheic dermatitis. Am Fam Physician. 2000;61:2703-2710, 2713-2714.
3. Grimalt R. A practical guide to scalp disorders. J Investig Dermatol Symp Proc. 2007;12:10-14.
4. Gupta AK, Madzia SE, Batra R. Etiology and management of seborrheic dermatitis. Dermatology. 2004;208:89-93.
5. Faergemann J. Management of seborrheic dermatitis and pityriasis versicolor. Am J Clin Dermatol. 2000;1:75-80.
6. Selden S. Seborrheic dermatitis. Emedicine [serial online]. http://www.emedicine.com/derm/topic396.htm. Updated March 10, 2009. Accessed May 12, 2009.
7. Gupta AK, Batra R, Bluhm R, et al. Skin diseases associated with Malassezia species. J Am Acad Dermatol. 2004; 51: 785-798.
8. Foley P, Zuo Y, Plunkett A, et al. The frequency of common skin conditions in preschool-aged children in Australia: seborrheic dermatitis and pityriasis capitis (cradle cap). Arch Dermatol. 2003; 139: 318-322.
9. Alexis AF, Sergay AB, Taylor SC. Common dermatologic disorders in skin of color: a comparative practice survey. Cutis. 2007; 80: 387-394.
10. Dawson TL Jr. Malassezia globosa and restricta: breakthrough understanding of the etiology and treatment of dandruff and seborrheic dermatitis through whole-genome analysis. J Investig Dermatol Symp Proc. 2007; 12: 15-19.
11. Elewski BE, Abramovits W, Kempers S, et al. A novel foam formulation of ketoconazole 2% for the treatment of seborrheic dermatitis on multiple body regions. J Drugs Dermatol. 2007;6:1001-1008.
12. Gupta AK, Kogan N. Seborrhoeic dermatitis: current treatment practices. Expert Opin Pharmacother. 2004;5: 1755-1765.
13. Gupta AK, Kohli Y, Li A, et al. In vitro susceptibility of the seven Malassezia species to ketoconazole, voriconazole, itraconazole, and terbinafine. Br J Dermatol. 2000; 142: 758-765.
14. Miranda KC, de Araujo CR, Costa CR, et al. Antifungal activities of azole agents against the Malassezia species. Int J Antimicrob Agents. 2007; 29: 281-284.
15. Zissova LG, Kantarjiev TB, Kuzmanov AH. Drug susceptibility testing of Malassezia furfur strains to antifungal agents. Folia Med (Plovdiv). 2001; 43: 10-12.
16. Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev. 2007; (3): CD001434.
17. Spergel JM, Leung DY. Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence. Curr Allergy Asthma Rep. 2006;6:270-274.
18. Ring J, Möhrenschlager M, Henkel V. The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy. Drug Saf. 2008; 31: 185-198.
19. Alsina M, Zemba C. Sertaconazol en la dermatitis seborreica del cuero cabelludo. Med Cut I L A. 1994; 22: 111-115.
20. Cited by: Torres J, Márquez M, Camps F. Sertaconazole in the treatment of mycoses: from dermatology to gynecology. Int J Gynaecol Obstet. 2000; 71(suppl 1): S3-S20.
21. Farré M, Ugena B, Badenas JM, et al. Pharmacokinetics and tolerance of sertaconazole in man after repeated percutaneous administration. Arzneimittelforschung. 1992; 42: 752-754.
22. Carillo-Muñoz AJ, Tur-Tur C. Comparative study of antifungal activity of sertaconazole, terbinafine, and bifonazole against clinical isolates of Candida spp, Cryptococcus neoformans and dermatophytes. Chemotherapy. 1997; 43: 387-392.
23. Carrillo-Muñoz AJ, Torres-Rodriguez JM. In-vitro antifungal activity of sertaconazole, econazole, and bifonazole against Candida spp. J Antimicrob Chemother. 1995;36: 713-716.
24. Palacin C, Sacristán A, Ortiz JA. In vitro comparative study of the fungistatic and fungicidal activity of sertaconazole and other antifungals against Candida albicans. Arzneimittelforschung. 1992;42:711-714.
25. Szlachcic A, Fillat O, Herrero E, et al. Eficacia y seguridad de Sertaconazol gel al 2% vs Ketoconazol gel al 2% en el tratamiento de la dermatitis seborreica del cuero cabelludo. XXVI Congreso Nacional de Dermatología. 29-31 mayo 1997. Benalmádena, Málaga.
26. Cited by: Torres J, Márquez M, Camps F. Sertaconazole in the treatment of mycoses: from dermatology to gynecology. Int J Gynaecol Obstet. 2000;71(suppl 1):S3-S20.
27. Ferrer Group Research Centre. Sertaconazole Product Monograph. Madrid, Spain: Content'Ed Net Communications SL; 2006.